MLSC Impact Catalyst
Connects non-dilutive milestone grant for seed-stage MA life science startups for research through the MLSC Impact Catalyst.
The MLSC Impact Catalyst is a non-dilutive seed grant program run by the Massachusetts Life Sciences Center (MLSC), a quasi-public state agency that has deployed more than $2 billion into the Massachusetts life sciences ecosystem since 2008. Impact Catalyst specifically targets early-stage Massachusetts life science startups working in five designated focus areas — Medical Devices and Diagnostics,…
Non-dilutive seed funding up to $250,000 for Massachusetts life science startups working in Medical Devices & Diagnostics, Health Equity, Women's Health, Psychiatric Diseases & Pain Management, or Microbiome & Antibiotics.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Guides for this application
All guides →Grants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
DocumentsGrant Work Plan Template: Work Packages, Gantt, Milestones, and Risks
Use this grant work plan template to structure work packages, tasks, owners, deliverables, Gantt timing, dependencies, and risk registers.
Submit & reportGrant Reporting Requirements: Post-Award Reports and Compliance
Learn what grant reporting requirements cover, how financial and performance reports work, what to track after an award, and how to avoid post-award compliance mistakes.
BudgetGrant Budget Justification: How to Write the Budget Narrative
Learn how to write a grant budget justification, explain R&D costs, avoid weak budget narratives, and connect each cost to your work plan.
More from MLSC
All grants from this funder →MLSC Internship Programs
🇺🇸MLSC · United States
Runs Paid internship subsidies across five tracks for MA life sciences employers through the MLSC Internship Programs.
MA Life Sciences Tax Incentive Program
🇺🇸MLSC · United States
Funds Massachusetts life science startups with tax incentives linked to commercialization-focused innovation milestones.
Massachusetts Life Sciences Tax Incentive Program
🇺🇸MLSC · United States
Helps life science companies in Massachusetts hire and retain permanent talent with refundable state tax incentives.
MassNextGen
🇺🇸MLSC · United States
Administers cohort for underrepresented MA life sciences founders non-dilutive grant lab through the MassNextGen.
MLSC Neuroscience Consortium
🇺🇸MLSC · United States
Invests in preclinical neuroscience teams at Massachusetts institutions through the MLSC Neuroscience Consortium to advance neurodegenerative research readiness.
MLSC Pathmaker
🇺🇸MLSC · United States
Supports Massachusetts organizations building life sciences career pathways aligned with hiring demand.
Similar grants
Browse the directory →
NCATS STTR Phase I
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to conduct feasibility studies on translational science innovations toward commercialization.
NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NSF SBIR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups demonstrating scientific feasibility of novel science and engineering innovations.
NSF STTR Phase I
🇺🇸NSF · United States
Funds United States deep-tech startups partnering with nonprofit research institutions for early-stage feasibility studies.
NIH SBIR Phase I
🇺🇸NIH SEED · United States
Funds early stage United States biomedical teams through NIH seed support for feasibility work on prototype ready ideas.
NCATS Preclinical Proof of Concept Studies for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies conducting preclinical efficacy studies to advance therapeutic candidates for rare diseases toward IND applications.